St. Jude Is a Fighter

St. Jude Medical (NYSE: STJ  ) is kicking the competition while they're down, but investors don't seem to have any problems with the medical device grudge match. In fact, they're quite enjoying it. St. Jude's stock was up as much as 10% since it released second-quarter results on Wednesday, though there's a slight pullback happening today.

Total sales were up 20%, with a major contribution from the company's cardiac rhythm management (CRM) segment. Past stumbles by competitors Medtronic (NYSE: MDT  ) and Boston Scientific (NYSE: BSX  ) , which have both had to issue recalls of their implantable cardioverter defibrillators (ICDs), could certainly have contributed. Of course, launching 40 new ICD and pacemaker products over the past two years hasn't hurt, either. St. Jude's ICDs, its largest product line at 35% of revenue, saw a jump of 24% year over year.

St. Jude management estimates that during the first half of the year, the company took between two and three points of ICD market share from its competitors. And that's on top of the two points it took last year. Not only does St. Jude have a larger share of the market, but management estimates that the CRM market, of which ICD is a large part, is still growing at a rate of 7% to 9%. Sometimes you can have your cake and eat it too.

Even sales in the biggest segment, cardiovascular, where it competes with Abbott Laboratories (NYSE: ABT  ) , increased by 14% over the year-ago quarter.

With increased sales have come better profit margins. Gross profit margin was up 140 basis points over the year-ago quarter, which shouldn't be a big surprise. St. Jude has improved its gross margin in each of the last 10 years. While operating and net income margin growth has been lumpier, each of these measures is also much improved over that time. The company should be able to make further improvements as it embarks on a long-term plan to revamp its manufacturing system.

A lot of that increased gross margin found its way to the bottom line -- net income was up 49% year over year. That's some serious Rule Breaker-sized growth.

St. Jude may be the patron saint of lost causes, but investors in St. Jude Medical have found cause to rejoice.

More Foolishness on medical device companies:

While St. Jude isn't a Rule Breakers pick, with numbers like the above, maybe it should be. Click here to see what companies have made it to such status with a free 30-day trial subscription.

Fool contributor Brian Orelli, Ph.D., hopes he doesn't get struck down for calling a company named after a saint a fighter. He doesn't own shares of any company mentioned in this article. The Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 688113, ~/Articles/ArticleHandler.aspx, 8/30/2014 4:26:39 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement